Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on ß-Cell function in normal living conditions  

Oleh:

Mari, Andrea ; Degn, Kristine ; Brock, Birgitte ; Rungby, Joergen ; Ferrannini, Ele ; Schmitz, Ole

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Diabetes Care vol. 30 no. 08 (Aug. 2007), page 2032.
Topik: Emerging Treatments and Technologies

Ketersediaan

Perpustakaan FK Nomor Panggil: D05.K.2007.03 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

INTRODUCTION Liraglutide is a long-acting glucagon-like peptide (GLP)-1 analog, which exerts its glucose-lowering action through multiple mechanisms. One important feature of liraglutide is its ability to enhance ß-cell function. The effects on ß-cell function have been demonstrated using standardized ß-cell function tests based on intravenous glucose administration. However, these studies may not reflect the modes of action of liraglutide during normal living. To assess the effects of liraglutide on ß-cell function in normal living, we have used a validated ß-cell model to analyze 24-h triple-meal experiments. RESEARCH DESIGN AND METHODS— This study includes data used for a different analysis in a previous publication (3), where the experimental protocol, approved by the local ethics committee and performed in accordance with the Helsinki Declaration, was described in detail. Thirteen type 2 diabetic patients (five women and eight men) were examined. Their mean ± SD age was 56.4 ± 9.2 years, BMI was 31.2 ± 3.6 kg/m2, last measured A1C before inclusion was 7.3 ± 0.4% (normal range <6.4%), and the duration of diabetes was 3.0 ± 2.6 years. The study is a randomized, double-blind, placebo-controlled, crossover trial, with a washout period of 6–7 weeks between treatments. After inclusion, the patients discontinued their oral hypoglycemic agents (sulfonylurea and metformin) for 2 weeks before the study. Liraglutide (6 µg/kg body wt) or placebo was injected subcutaneously into the abdomen once daily (at 0745 h) for 9 days. After 7 days of treatment, the patients where hospitalized at 2200 h. On the next day, while continuing treatment, three standard meals were served at 0800, 1200, and . . .

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali